NASDAQ$INDV
Indivior Pharmaceuticals Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
INDV Q3 2024 — extraction skipped
Indivior Pharmaceuticals Inc filed Form 6-K/A (accession 0001625297-25-000009) for Q3 2024, but headline financial numerics could not be extracted automatically: no headline numerics found by parser nor by Financial Datasets fallback. The row is marked as AI-processed so the queue advances; numerics will be filled by Financial Datasets on its next pass.
- Form 6-K/A filed; press release body not parseable here.
- Reason: no headline numerics found by parser nor by Financial Datasets fallback.
- Numerics rely on the Financial Datasets fallback.
Headline financials
Revenue & EPS history
Indivior · Revenue · Quarterly
$307M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q3 2024
+7.2%
Avg return
Earnings day
+12.4%
Avg return
5 days after
+871.4%
Avg return
30 days after
73%
8 / 11 earnings
Positive
+24.4%
Q4 2023
Best reaction
-16.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +7.7% | +15.9% | — | |
| Q4 2025 | +0.2% | -8.2% | -13.9% | |
| Q3 2025 | +15.4% | +26.8% | +33.1% | |
| Q2 2025 | +16.1% | +25.3% | +39.5% | |
| Q1 2025 | +17.3% | +24.3% | +8632.9% | |
| Q3 2024 | +7.0% | +7.0% | +27.1% | |
| Q2 2024 | +19.2% | +8.3% | -5.4% | |
| Q1 2024 | -7.0% | +25.5% | +13.1% | |
| Q4 2023 | +24.4% | +27.1% | +19.3% | |
| Q3 2023 | -16.0% | -9.4% | -21.5% | |
| Q2 2023 | -5.4% | -6.8% | -10.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro